Silva Pharmaceuticals Limited (DSE:SILVAPHL)
Bangladesh · Delayed Price · Currency is BDT 9.90
+0.10 (1.02%)
At close: Dec 3, 2025
Silva Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2016 - 2020 |
| 370.96 | 383.65 | 599.66 | 716.87 | 778.67 | 799.25 | Upgrade | |
Revenue Growth (YoY) | -32.19% | -36.02% | -16.35% | -7.94% | -2.57% | 4.71% | Upgrade |
Cost of Revenue | 275.56 | 283.13 | 437.91 | 487.58 | 492.89 | 486.26 | Upgrade |
Gross Profit | 95.4 | 100.51 | 161.75 | 229.29 | 285.78 | 312.99 | Upgrade |
Selling, General & Admin | 219.12 | 221.52 | 209.99 | 185.61 | 175.07 | 171.85 | Upgrade |
Other Operating Expenses | -0.66 | -0.66 | -1.05 | -1.1 | -1.05 | -0.94 | Upgrade |
Operating Expenses | 218.46 | 220.87 | 208.95 | 184.51 | 174.02 | 170.91 | Upgrade |
Operating Income | -123.07 | -120.35 | -47.2 | 44.78 | 111.76 | 142.09 | Upgrade |
Interest Expense | -4.47 | -4.48 | -4.38 | -3.61 | -4.71 | -2.78 | Upgrade |
Interest & Investment Income | 5 | 5.34 | 5.17 | 9.45 | 9.67 | 12.05 | Upgrade |
Other Non Operating Income (Expenses) | -0.18 | -0.08 | -0.08 | -0.26 | -0.05 | -0.02 | Upgrade |
Pretax Income | -122.72 | -119.58 | -46.5 | 50.36 | 116.67 | 151.35 | Upgrade |
Income Tax Expense | 13.21 | 13.37 | 17.99 | 17.29 | 14.41 | 31.49 | Upgrade |
Net Income | -135.93 | -132.95 | -64.48 | 33.08 | 102.26 | 119.85 | Upgrade |
Net Income to Common | -135.93 | -132.95 | -64.48 | 33.08 | 102.26 | 119.85 | Upgrade |
Net Income Growth | - | - | - | -67.65% | -14.68% | 0.77% | Upgrade |
Shares Outstanding (Basic) | 137 | 137 | 137 | 137 | 137 | 137 | Upgrade |
Shares Outstanding (Diluted) | 137 | 137 | 137 | 137 | 137 | 137 | Upgrade |
EPS (Basic) | -1.00 | -0.97 | -0.47 | 0.24 | 0.75 | 0.88 | Upgrade |
EPS (Diluted) | -1.00 | -0.97 | -0.47 | 0.24 | 0.75 | 0.88 | Upgrade |
EPS Growth | - | - | - | -67.65% | -14.68% | 0.92% | Upgrade |
Free Cash Flow | 20.38 | 6.49 | -29.57 | -16.7 | -16.8 | 82.22 | Upgrade |
Free Cash Flow Per Share | 0.15 | 0.05 | -0.22 | -0.12 | -0.12 | 0.60 | Upgrade |
Dividend Per Share | - | - | 0.100 | 0.100 | 0.300 | 0.500 | Upgrade |
Dividend Growth | - | - | - | -66.67% | -40.00% | - | Upgrade |
Gross Margin | 25.72% | 26.20% | 26.97% | 31.99% | 36.70% | 39.16% | Upgrade |
Operating Margin | -33.17% | -31.37% | -7.87% | 6.25% | 14.35% | 17.78% | Upgrade |
Profit Margin | -36.64% | -34.65% | -10.75% | 4.61% | 13.13% | 15.00% | Upgrade |
Free Cash Flow Margin | 5.50% | 1.69% | -4.93% | -2.33% | -2.16% | 10.29% | Upgrade |
EBITDA | -66.62 | -62.52 | 11.59 | 107.29 | 174.33 | 207.38 | Upgrade |
EBITDA Margin | -17.96% | -16.30% | 1.93% | 14.97% | 22.39% | 25.95% | Upgrade |
D&A For EBITDA | 56.44 | 57.83 | 58.79 | 62.51 | 62.57 | 65.29 | Upgrade |
EBIT | -123.07 | -120.35 | -47.2 | 44.78 | 111.76 | 142.09 | Upgrade |
EBIT Margin | -33.17% | -31.37% | -7.87% | 6.25% | 14.35% | 17.78% | Upgrade |
Effective Tax Rate | - | - | - | 34.33% | 12.35% | 20.81% | Upgrade |
Advertising Expenses | - | 5.37 | 3.82 | 3.81 | 5.92 | 20.65 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.